业务范围
基于强大的研发力量，创造人类健康生活。
生命科学作为中长期培养的未来新成长事业领域，拥有韩国首个获得美国 FDA 新药认证的创新的研发力量。
走出韩国，积极攻略海外市场，通过积极的投资和研发，扩大新药开发渠道，致力于成长为全球制药公司。
销售额
Life Science Sales Graph Business Areas LG Chem Life Science Sales Graph Business Areas LG Chem
销售额 :2022 ,2023 ,2024
2022 0.9
2023 1.2
2024 1.3

单位 : 兆韩元

  • 2024 向美国公司‘Rhythm Pharmaceuticals’
    出口稀有肥胖药物技术
  • 2023 收购美国抗癌新药企业AVEO
  • 2022 生长激素治疗药物Eutropin S PEN上市
  • 2021 在中国成立爱尔集健生合资销售公司
  • 2019 在美国成立波士顿全球创新中心
  • 2017 （原）LG 生命科学
    合并
  • 2012 推出韩国首个糖尿病治疗药物
    “Zemiglo”
  • 2003 喹诺酮类抗生素“Factive”
    获美国 FDA 新药认可
  • 1996 乙型肝炎疫苗Euvax B
    韩国首获WHO PQ批准
  • 1991 全球最早研发
    第 4 代头孢菌素类抗生素
  • 1984 新设
    医药事业部
  • 1961 取得药品生产许可证
事业部
Primary Care业务部 Business Areas LG Chem Primary Care业务部
Specialty Care业务部 Business Areas LG Chem Specialty Care业务部
美容业务部 Business Areas LG Chem 美容业务部
浏览相关产品 ▶
VISION

致力于成为世界一流的新药研发企业

  • 到2030年拥有5款以上新药
  • 提高新药研发管线质量
  • 研发投入超3千亿韩元
  • 加强开放式创新
  • 抗癌、免疫、糖尿病、代谢性疾病
  • 开发阶段建立新药研发管线
  • 开发阶段建立新药研发管线 :2024 ,2030
    2024 12个
    2030 20个

    探索 研究 临床前 临床

  • 加速推进全球临床开发 及业务增长
  • 扩大全球临床开发课题
  • AVEO公司美国抗癌业务持续增长
LG化学生命科学药物管线

  • Diabetes & Metabolism
  • Oncology & Immunology
  • Cell Therapy
  • Vaccine
  • Aesthetic
  1. Preclinical(4)
    • LR19023 LR19023Oncology
      LR19023
      해당 프로젝트 팝업
      Molecule LR19023
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
    • LR19128 LR19128Oncology
      LR19128
      해당 프로젝트 팝업
      Molecule LR19128
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner Avactar Life sciences

      Affimer® Technology

    • LR20061 LR20061Atopic Dermatitis
      LR20061
      해당 프로젝트 팝업
      Molecule LR20061
      Stage Preclinical
      Indication Atopic Dermatitis
      Modality Chemical
      Target Undisclosed
    • LR19157 LR19157Oncology
      LR19157
      해당 프로젝트 팝업
      Molecule LR19157
      Stage Preclinical
      Indication Oncology
      Modality Chemical
      Target Undisclosed
  2. Phase I(8)
    • LR19129 CUE-102Oncology
      LR19129
      해당 프로젝트 팝업
      Molecule CUE-102
      Stage Phase 1 (by Partner)
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target WT-1
      Partner Cue Biopharma
    • LR19127 CUE-101HNSCC
      LR19127
      해당 프로젝트 팝업
      Molecule CUE-101
      Stage Phase 1 (by Partner)
      Location summary USA
      Indication HNSCC
      Modality Biologics
      Target HPV
      Partner Cue Biopharma
    • LR19125 PDC*LungNSCLC
      LR19125
      해당 프로젝트 팝업
      Molecule PDC*Lung
      Stage Phase 1 (by Partner)
      Location summary Europe
      Indication NSCLC
      Modality Cell therapy
      Target Cancer vaccine
      Partner PDC*line Pharma
    • LR20011 GEN-001Solid tumor
      LR20011
      해당 프로젝트 팝업
      Molecule GEN-001
      Stage Phase 1 (by Partner)
      Location summary USA
      Indication Solid tumor
      Modality Microbiome
      Target Microbiome
      Partner Genome & Company
    • AV-380 AV-380Cachexia
      AV-380
      해당 프로젝트 팝업
      Molecule AV-380
      Stage Preclinical
      Location summary USA
      Indication Cachexia
      Modality Biologics
      Target anti-GDF15 IgG1 mAb
    • AV-203 AV-203Oncology
      AV-203
      해당 프로젝트 팝업
      Molecule AV-203
      Stage Phase 1
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target Anti-ERBB3 IgG1 mAb
    • LR19155 LR19155Oncology
      LR19155
      해당 프로젝트 팝업
      Molecule LR19155
      Stage Phase 1
      Indication Oncology
      Modality Biologics
      Target LILRB1
    • LR19018 LG203003NASH
      LR19018
      해당 프로젝트 팝업
      Molecule LG203003
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target DGAT-2
  3. Phase II(5)
    • LR20062 aP vaccine
      LR20062
      해당 프로젝트 팝업
      Molecule aP vaccine
      Stage Phase 2
      Indication aP vaccine
      Modality Vaccine
      Target aP vaccine

      Diphtheria, Tetanus, Pertussis,Polio, Hib, HebB

    • LR19021 LB54640Genetic Obesity
      LR19021
      해당 프로젝트 팝업
      Molecule LB54640
      Stage Phase 2
      Location summary USA
      Indication Genetic Obesity
      Modality NCE
      Target MC4R
    • LR19114 6 in 1 Vaccine
      LR19114
      해당 프로젝트 팝업
      Molecule 6 in 1 Vaccine
      Stage Phase 2
      Indication 6 in 1 Vaccine
      Modality Vaccine
      Target 6 in 1 Vaccine

      Diphtheriae (D), Bordetella pertussis (wP), Clostridium tetani (T), Hepatitis B (HepB) Haemophilus influenzae type b(Hib) Vaccine-Associated Paralytic Poliomyelitis(IPV)

    • LR19019 ZectivimodUlcerative colitis Atopic dermatitis
      LR19019
      해당 프로젝트 팝업
      Molecule Zectivimod
      Stage Phase 2 (by Partner)
      Location summary China
      Indication Ulcerative colitis Atopic dermatitis
      Modality NCE
      Target S1P1
      Partner TransThera (License-out)

      License-out, China

    • LR19024 LG34053Osteoarthritis
      LR19024
      해당 프로젝트 팝업
      Molecule LG34053
      Stage Phase 1b/2
      Location summary Republic of Korea
      Indication Osteoarthritis
      Modality NCE
      Target Undisclosed
  4. Phase III(2)
  5. NDA(2)
    • LR20024 Y-solution, MDRHA filler
      LR20024
      해당 프로젝트 팝업
      Molecule Y-solution, MDR
      Stage NDA
      Location summary Europe
      Indication HA filler
      Modality HA
      Target HA
    • LR19094 Y-solution, ChinaHA filler
      LR19094
      해당 프로젝트 팝업
      Molecule Y-solution, China
      Stage NDA
      Location summary China
      Indication HA filler
      Modality HA
      Target HA
Image Download 다운로드
主要产品
Eutropin Business Areas LG Chem Eutropin
Hyruan One Business Areas LG Chem Hyruan One
Zemiglo / Zemimet SR Tab. / Zemidapa Business Areas LG Chem Zemiglo / Zemimet SR Tab. / Zemidapa
Eucept Business Areas LG Chem Eucept
YVOIRE Business Areas LG Chem YVOIRE
新闻稿
LG化学全球不孕不育与生殖医学研讨会“FAME Global 2024”圆满结束 2024.08.08
LG化学全球不孕不育与生殖医学研讨会“FAME Global 2024”圆满结束 2024.08.08
LG化学全球不孕不育与生殖医学研讨会“FAME Global 2024”圆满结束 2024.08.08
more